Investigators at the University of the Witwatersrand have shown that the vaccine regimen used in the RV-144 "Thai" trial, the first trial to demonstrate any protective efficacy for an HIV vaccine, elicited a stronger immune response in a South African cohort than it had in the original Thai cohort.

Canbridge Pharmaceuticals Inc., of Beijing, appointed Lisa Li vice president, rare disease, and Guofang Liu, head of market access.